This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in RNA Interference. Top assignees: Nitto-Denko Corporation, Alnylam Pharmaceuticals, Inc., Imperial College of Science, Technology and Medicine. Active years: 2011-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Boston, MA (US) (2011 - 2015)
- Carlsbad, CA (US) (2017 - 2023)
- San Diego, CA (US) (2019 - 2024)
Company Filing History:
10 out of 3,959 
2 out of 467 
1 out of 112 
Years Active: 2011-2024
Areas of Expertise:
Title: Jens Harborth: Innovator in Genetic Research
Introduction
Jens Harborth is a prominent inventor based in Boston, MA, renowned for his significant contributions to genetic research. With two patents to his name, he has made strides in the field of biotechnology, particularly in the inhibition of gene expression.
Latest Patents
Jens Harborth's latest patents focus on "Compositions and methods for inhibiting expression of the IKK-B gene." This invention pertains to a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of the IKK-B gene. The dsRNA includes an antisense strand with a nucleotide sequence of less than 30 nucleotides, typically ranging from 19 to 25 nucleotides, which is substantially complementary to parts of the IKK-B gene. The invention also encompasses a pharmaceutical composition containing this dsRNA along with a pharmaceutically acceptable carrier. Moreover, it introduces methods for treating diseases associated with the expression or activation of the IKK-B gene, as well as methods for inhibiting the gene's expression in a cell.
Career Highlights
Throughout his career, Jens Harborth has contributed extensively to biotechnology and genetic innovation. He has worked at Alnylam Pharmaceuticals, Inc., a leader in RNA interference therapeutics, and at the Imperial College of Science, Technology and Medicine, where he has engaged in groundbreaking research that advances our understanding of gene regulation.
Collaborations
Jens has collaborated with notable colleagues in his field, including Antonin de Fougerolles and Andrew Sprague. These collaborations have enriched his research endeavors and allowed for the sharing of knowledge and expertise in genetic engineering.
Conclusion
With a focus on innovative genetic therapies, Jens Harborth stands out as a key inventor in his field. His patents not only reflect his commitment to scientific advancement but also hold the potential for significant impact on therapeutic strategies for diseases linked to the IKK-B gene. His ongoing work continues to inspire future innovations in biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile